Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H. Bliss, Jr., EntreMed's Senior Vice President, Corporate and Business Development, will present a Company overview at the 16th Annual BioPartnering Europe Conference, which is being held October 12-14, 2008 in London, United Kingdom. Mr. Bliss' presentation is scheduled for Monday, October 13, 2008 at 12:15 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Bliss will provide an overview of the Company's clinical-stage programs, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoid arthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for the treatment of cancer, is in a multi-center Phase 1b dose-escalation study in patients with solid tumors. Panzem(R) (2ME2), an orally-active small molecule angiogenesis inhibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development and commercialization of these novel drug candidates.

Mr. Bliss's presentation will not be web cast; however, a copy of his presentation will be available through the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical compa
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... , ... Sleepless nights will become obsolete as Luzi , a sophisticated ... on June 23. Sound sleepers and the sleep deprived both will love Luzi for ... the integration of the Bluetooth speaker, alarm clock and ability to charge various devices, ...
(Date:7/1/2015)... ... , ... It is now possible to separate two common disorders: post-traumatic stress ... (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and University ... believed to be the largest brain imaging study ever, will be published on July ...
(Date:7/1/2015)... Mass. , July 1, 2015   ... most frequently cited advantages of Otezla are its ... safety profile, as reported by surveyed rheumatologists. Otezla ... launched for the treatment of active psoriatic arthritis ... The current standard of care includes conventional oral ...
(Date:7/1/2015)... Colo. and BANGALORE, India ... global genomic profiling company that uses next generation sequencing ... of Scott A. Storrer as chief executive ... CEO, he will be responsible for all strategy, business ... Chandru , who has served as Strand,s chairman and ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... epigenetic anticancer program at Pharmion ... inhibitors - ... Significant opportunity to explore combination epigenetic therapies, BOULDER, Colo. ... and MethylGene Inc. (TSX: MYG) today announced a,research collaboration for ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: ... increased more than,35% over the first quarter of 2007 ... for the same period in the previous year. ... compared to only,$24,374 in the first half of 2006. ...
... COLUMBIA, Md., Aug. 14 Martek Biosciences,Corporation announced that ... of fiscal 2007 on September 5, 2007, at approximately ... 4:45 p.m. EDT Martek,will hold a conference call to ... with investors. The call is expected to be approximately ...
Cached Biology Technology:Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6Martek to Announce Third Quarter 2007 Results on September 5, 2007 2
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... Galton-Darwin-Wedgwood pedigree was prepared by Harry Hamilton Laughlin, Director ... and exhibited at the Third International Congress of Eugenics ... A photograph of this poster has been discovered ... Missouri alongside a photograph of a poster of a ...
... are launching a new series of podcasts this week entitled ... Save Our Seas Foundation (SOSF), investigate various topics of ocean ... Sarah Castor-Perry, both members of the Naked Scientists team and ... With the help of expert guests, they ...
... an important military, communication, aviation, and shipping hub of ... Korea and the Philippines has resulted in the arrival ... his team will develop, demonstrate and facilitate the adoption ... will enable growers to transition away from the use ...
Cached Biology News:New 'Naked Scientists' series investigates our oceans 2
... This reagent is formulated specifically for ... consistently high levels of activity for both ... storage at final dilution. This product ... stability providing the customer a longer shelf ...
... Microarray Slide features an ultra-thin nitrocellulose ... is the first protein microarray slide ... nitrocellulose in a thin film with ... ,The PATH™ Slide can be ...
... Hybridization Cassettes facilitate the hybridization of DNA ... standard 25mm x 75mm glass slides. The ... to correct for poor flatness, as is ... its low volume chamber (67uL analytical cavity ...
... monoclonal [3D12] to Lambda Free Light ... of light chains of human immunoglobulin. ... independent constantly expressed epitope of lambda ... forms of free lambda chains but ...
Biology Products: